BioGaia® Osfortis® winner of the NutraIngredients Awards 2022
We are proud to announce that our probiotic for bone health, Osfortis, is the winner of the 2022 NutraIngredients Awards in the category “Innovations in Women’s Health Award”.
Postmenopausal women are at high risk of developing osteoporosis as the drop in oestrogen levels during menopause is directly linked to reduced bone mass. Therefore, many women seek preventative measures. Osfortis contains the patented probiotic strain L. reuteri ATCC PTA 6475, in combination with vitamin D, which contributes to the maintenance of normal bones.
Since 2016, the NutraIngredients Awards honour the best and brightest ingredients, finished products and innovations in nutrition and dietary supplements. This year, a new category was introduced – “Innovations in Women's Health Award”, which recognizes innovators with the best ingredients or products to promote women’s health.
Ewa Hudson, Director of Insights at Lumina Intelligence headed up the panel of judges, made up of industry experts. The motivation from the jury was:
“BioGaia Osfortis is a probiotic product that helps postmenopausal women stay healthy and active longer, and we are impressed by the strength of the clinical evidence showing the efficacy of L. reuteri in reducing bone loss”.
– Osteopenia is a silent disease responsible for many fractures in the elderly population. We are very proud to be able to offer a totally natural probiotic product without side effects, proven to reduce bone loss in older women, as shown in the clinical study by Principal investigator, Professor Mattias Lorentzon, says Isabelle Ducellier, CEO of BioGaia.
Read more about: BioGaia Osfortis (link)
Read more about: NutraIngredients Awards 2022 (link)
Read more about: The clinical trial by Professor M. Lorentzon (link)
For more information, please contact:
Isabelle Ducellier, CEO
+46 8 555 293 00
Latest press releases from BioGaia
06.05.2022 Annual General Meeting of BioGaia
06.05.2022 Record date for share division (split) in BioGaia AB
06.05.2022 Interim report January - March 2022